Progress in using order of noval endocrine agents for the treatment of castration-resistant prostate cancer / 肿瘤

ABSTRACT

The incidence of prostate cancer in China has a rising trend recently. The majority of prostate cancer patients have been in advanced stage at the first diagnosis. Although the endocrine therapy may make prostate cancer under control and improvement in a certain period of time, but almost patients will finally develop to metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis after 18-24 months of remission period. Because mCRPC is difficult to cure, it is urgent to optimize the treatment strategy for improving efficacy. The current evidence shows that the new endocrine drugs such as abiraterone and enzalutamide combined with docetaxel chemotherapy can provide survival benefit for the patients with mCRPC, but there is still a controversy about the optimal using order of these agents. The article reviews the clinical trials on the treatment sequencing of noval endocrine agents in docetaxel-experienced and docetaxel-naive patients with mCRPC in order to provide the basis for the correct selection of treatment strategies, and thus to prolong the overall survival and improve the quality of life of the patients.